no statement of use filed
on 22 Mar 2021
Last Applicant/ Owned by
75 Hayden Avenue
Lexington
MA
02421
Serial Number
87315569 filed on 27th Jan 2017
Registration Number
N/A
Correspondent Address
Glenn A. Gundersen
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silRead More
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
Custom manufacture of oligonucleotides for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections
No 87315569
No Service Mark
No 166233-006
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 22nd Mar 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 22nd Mar 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| 25th Feb 2021 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 25th Feb 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 25th Feb 2021 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 19th Aug 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 18th Aug 2020 | EXTENSION 5 GRANTED |
| 18th Aug 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 12th Aug 2020 | TEAS EXTENSION RECEIVED |
| 12th Aug 2020 | EXTENSION 5 FILED |
